VTFN Stock Overview
Provides assisted reproduction products. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Vitrolife AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 18.95 |
| 52 Week High | SEK 23.98 |
| 52 Week Low | SEK 13.25 |
| Beta | 1.8 |
| 11 Month Change | -8.89% |
| 3 Month Change | -2.62% |
| 1 Year Change | 27.44% |
| 33 Year Change | -62.88% |
| 5 Year Change | 8.53% |
| Change since IPO | 3,544.23% |
Recent News & Updates
Recent updates
Shareholder Returns
| VTFN | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 2.2% | -0.7% | -0.02% |
| 1Y | 27.4% | -17.2% | 8.2% |
Return vs Industry: VTFN exceeded the German Biotechs industry which returned -17.2% over the past year.
Return vs Market: VTFN exceeded the German Market which returned 8.2% over the past year.
Price Volatility
| VTFN volatility | |
|---|---|
| VTFN Average Weekly Movement | 7.5% |
| Biotechs Industry Average Movement | 6.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: VTFN's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: VTFN's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | 1,111 | Bronwyn Brophy O´Connor | www.vitrolife.com |
Vitrolife AB (publ) provides assisted reproduction products. It also offers sperm processing, oocyte retrieval needles, micromanipulation pipettes, time-lapse systems, and evaluation tools, laser and imaging systems, IVF media and oil, embryo transfer, cryopreservation, and genomics kits. In addition, the company offers EmbryoScope and time-lapse systems; time-lapse dishes; and evaluation tools for time-lapse systems.
Vitrolife AB (publ) Fundamentals Summary
| VTFN fundamental statistics | |
|---|---|
| Market cap | €2.61b |
| Earnings (TTM) | -€330.87m |
| Revenue (TTM) | €309.14m |
8.4x
P/S Ratio-7.9x
P/E RatioIs VTFN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VTFN income statement (TTM) | |
|---|---|
| Revenue | SEK 3.56b |
| Cost of Revenue | SEK 1.49b |
| Gross Profit | SEK 2.07b |
| Other Expenses | SEK 5.87b |
| Earnings | -SEK 3.80b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Jan 30, 2025
| Earnings per share (EPS) | -28.10 |
| Gross Margin | 58.17% |
| Net Profit Margin | -107.03% |
| Debt/Equity Ratio | 14.6% |
How did VTFN perform over the long term?
See historical performance and comparison